Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors (NCT06625775)

🧪 Interventions in This Study

• BBO-10203 (DRUG)
• Trastuzumab (DRUG)
• Fulvestrant (DRUG)
• Ribociclib (DRUG)
• FOLFOX (DRUG)
• Bevacizumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (40 Sites)

Showing the first 25 of 40 sites.

• City of Hope Comprehensive Cancer Center — Duarte, California
• University of California Los Angeles — Los Angeles, California
• University of California San Diego Moores Cancer Center — San Diego, California
• UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
• Moffitt Cancer Center — Tampa, Florida
• Indiana University Simon Comprehensive Cancer Center — Indianapolis, Indiana
• Massachusetts General Hospital — Boston, Massachusetts
• Dana-Farber Cancer Insitute — Boston, Massachusetts
• St. Lukes Hospital of Kansas City — Kansas City, Missouri
• Washington University School of Medicine — St Louis, Missouri
• Columbia University Irving Medical Center — New York, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• SCRI Oncology Partners — Nashville, Tennessee
• SCRI at Mary Crowley — Dallas, Texas
• University of Texas Southwestern Medical Center — Dallas, Texas
• The University of Texas MD Anderson Cancer Center — Houston, Texas
• University of Texas San Antonio (UTSA) — San Antonio, Texas
• Fred Hutchinson Cancer Center — Seattle, Washington
• Wisconsin Institute for Medical Research — Madison, Wisconsin
• Scientia Clinical Research — Randwick, New South Wales
• Peter MacCallum Cancer Centre — Melbourne, Victoria
• FUTTURA Oncologia — Porto Alegre, Rio Grande do Sul
• Hospital São Lucas da PUCRS — Porto Alegre, Rio Grande do Sul
• Clinica de Pesquisas e Centro de Estudos Em Oncologia Ginecologica e Mamaria Ltda — São Paulo, São Paulo
• IEPE - Unimed Sorocaba — Sorocaba, São Paulo

📞 Contact the Study Coordinator

Phone: (650) 405-8440

Email: Breaker-101ct.gov@bridgebiooncology.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Solid Tumor, Adult

• A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody — Sarasota, Florida
• First-in-Human Study of ICT01 in Patients With Advanced Cancer — Gilbert, Arizona
• A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors — Los Angeles, California
• Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab — Los Angeles, California
• A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial — Scottsdale, Arizona
• A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression — Gilbert, Arizona

Explore by condition: All Solid Tumor, Adult clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.